The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 100 German Patient Groups - 4th edition
- Published Wednesday, 5th July 2017
- Part of a series of reports offered by PatientView
- Format is PDF (107 pages)
- These results are derived from a global review
of pharma’s corporate reputation (conducted November 2016 to early-February 2017).
- The results form the opinions of 100 German patient groups: 22 specialised in cancer; 11 in mental health; 8 in rare diseases; 6 in multiple sclerosis; and other specialties.
- 21 pharma companies are included in this 2016 German analysis: •
Amgen (new to the German analysis) • AstraZeneca • Bayer • Biogen (new) • Boehringer Ingelheim • Bristol-Myers Squibb • Eli Lilly (Lilly) • Grünenthal •
GSK • Janssen • Merck & Co • Merck KGaA • Novartis • Novo Nordisk (new) • Pfizer • Roche • Sandoz •
Sanofi • Stada Arzneimittel • Takeda (new) • Teva (new). The 21 companies were chosen because a minimum of 19 German patient groups declared familiarity with each one.
- In response to a survey of pharmaceutical companies, only Bayer Vital GmbH provided information on its patient centricity and relations with patient-advocacy groups during 2016-2017 in Germany.
Industry-wide questions: - How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma
industry’s corporate reputation has changed over the past five years.
- How good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators show the corporate reputation of individual pharma companies: - Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of products.
- Transparency.
- Integrity.
- Patient-group relationships
(new for 2016).
- In 2016, only 19% of German patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation, compared with 38% of patient groups worldwide.
- The 2016 results were the most negative ratings from German patient groups since 2012.
- German patient groups ranked the pharma industry 7th in 2016 among eight healthcare-industry sectors for having an “Excellent” or “Good” corporate reputation. By contrast, patient groups from all geographic areas ranked pharma 5th in 2016.
- German patient groups were, however, more positive about the industry's levels of innovation, and about its ability to create high-quality products
[see chart, below]. 54% and 55% of the 100 German patient groups described pharma as “Excellent” or “Good” at these two activities in 2016, respectively.
- However, the pharmaceutical industry was marked down by German patient groups for its other activities—most notably, fair pricing. Just 3% of the 100 German patient groups called pharma “Excellent” or “Good” at this activity in 2016. Only patient groups from Ireland and the Netherlands graded pharma lower for this activity (with a score of zero).
% of respondent German patient groups in 2016 describing pharma as “Excellent” or “Good” at having high-quality products
% of respondent German patient groups describing pharma as “Excellent” or “Good” at having fair pricing policies
PHARMA COMPANIES and GERMAN PATIENT GROUPS
- The company with which German patient groups were most familiar in 2016 was Roche (73 of the 100 respondent German patient groups were familiar with the company), followed by Novartis (71), and Pfizer (69).
Levels of familiarity among German patient groups with the 21 featured pharma companies, 2016. Number of respondent German patient groups saying that they were familiar with the company
INDIVIDUAL COMPANY FINDINGS—GERMANY
- Amgen (new to the German analysis) ranked overall 1st in 2016 for corporate reputation among the 23 respondent German patient groups familiar with the company.
- Amgen also ranked 1st in 2016 for four of the seven indicators
of corporate reputation. The exceptions were patient safety, provision of high-quality products, and integrity.
- Novo Nordisk (also new to the German analysis) was ranked 1st in 2016 for these latter three indicators by the 19 respondent German patient groups familiar with the company.
If the German corporate-reputation results for 2016 (21 pharma companies analysed) are compared with those of 2015 (16 pharma companies analysed) using a standardised index—the Patient Corporate Reputation Index (PCRI)—findings show the biggest jumps up the German rankings were for:
Merck & Co, which ranked 11th overall out of 21 companies in 2016 (compared with 15th out of 16 companies in 2015).
AstraZeneca, which ranked 9th overall out of 21 companies in 2016 (compared with 12th out of 16 companies in 2015).
Bristol-Myers Squibb, which ranked 7th out of 21 companies overall in 2016 (compared with 10th out of 16 companies in 2015).
CONTENTS, TABLES and CHARTS—GERMANY
Contents - Executive summary.
- German patient-group relationships with
pharma. - Industry-wide findings from German patient groups.
- German patient groups on improving
corporate reputation. - Rankings of the 21 pharma companies among German patient groups FAMILIAR with them.
- Profiles of the 21 pharma companies.
- Comments from respondent German patient groups.
- Profile of the 100 respondent German patient
groups.
- Bayer Vital GmbH: response to PatientView pharma survey on patient centricity and patient-group relationships.
Company profiles: - Rankings among German patient groups for the indicators of corporate reputation among patient groups familiar
with the company, 2016.
- The company's average scores for the 7 indicators of corporate reputation, 2016 versus 2015.
- The company’s performance for the 7 indicators of corporate reputation, 2016.
- The company’s rankings among patient groups for the indicators of corporate reputation, 2016: Germany versus worldwide.
- Percentage of the patient groups that worked
with the company—but which also worked with other companies, 2016.
- How the company did at corporate reputation in different therapy areas, compared with its German average, 2016.
For more information about this German analysis, please use contact details below.
|